Home › Trial NCT00838357
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
- Trial IDNCT00838357
- StatusCompleted
- PhasePhase 3
- Study typeInterventional
- SponsorGenzyme, a Sanofi Company
- Enrollment118
- Start date2008-09
- ConditionsLymphoma (Non-Hodgkin's Lymphoma) · Hodgkin's Disease or Multiple Myeloma · Front Line Mobilization · Transplantation
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.